← Browse by Condition
Medical Condition

metastatic nasopharyngeal carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for metastatic nasopharyngeal carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — metastatic nasopharyngeal carcinoma Clinical Trials

How many clinical trials are currently recruiting for metastatic nasopharyngeal carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for metastatic nasopharyngeal carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for metastatic nasopharyngeal carcinoma?
metastatic nasopharyngeal carcinoma research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a metastatic nasopharyngeal carcinoma clinical trial?
Eligibility criteria for metastatic nasopharyngeal carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
Sun Yat-sen University 1 trial
National Cancer Institute (NCI) 1 trial
Chen Xiaozhong 1 trial

Recruiting Clinical Trials

NCT06802835 Phase 1, Phase 2
Recruiting
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Enrollment
148 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06029270 Phase 2
Recruiting
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Enrollment
156 pts
Location
United States, Austr...
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT06886347 Phase 1
Recruiting
Metastatic Nasopharyngeal Carcinoma
Enrollment
47 pts
Location
China
Sponsor
Chen Xiaozhong
View Trial →

Related Conditions

nasopharyngeal cancinoma npc (1) recurrent nasopharynx carcinoma (1) recurrent nasopharyngeal carcinoma (1) stage iv nasopharyngeal carcinoma ajcc v8 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology